BioNTech has acquired Neon Therapeutics in an all stock transaction valued at $2.18...
- BioNTech acquires T cell therapy-focused Neon for $67m
- MorphoSys and Incyte sign $900m deal for B-cell malignancies drug
- Pfizer signs oncology agreement with STR-focused eFFECTOR
- Merck collaborates on small molecule inhibitors with Taiho and Astex
- China in 2019: a prime destination for pharma R&D deals
BioNTech acquires T cell therapy-focused Neon for $67m
BioNTech has acquired Neon Therapeutics in an all stock transaction valued at $2.18 per share or approximately $67m. According to the terms of the deal, Neon will be merged with ENDOR Lights, a wholly owned subsidiary of BioNTech.
Merck closes $2.7bn acquisition of biopharmaceutical firm ArQule
Merck (MSD) has completed its previously announced acquisition of US-based biopharmaceutical company ArQule.
MorphoSys and Incyte sign $900m deal for B-cell malignancies drug
Germany-based MorphoSys has announced it has signed a collaboration and license agreement with the US company Incyte to continue the global development and commercialisation of the former’s tafasitamab (MOR208) for B-cell malignancies.
Pfizer signs oncology agreement with STR-focused eFFECTOR
San Diego-based eFFECTOR has signed an exclusive worldwide license and collaboration agreement with Pfizer in the oncology field.
Almirall signs option agreement to acquire Bioniz Therapeutics
Spanish drugmaker Almirall has signed an option agreement to acquire Bioniz Therapeutics, a clinical-stage biopharmaceutical company in California.
Galen acquires Nordic-based POA Pharma in multi-million pound deal
Northern Ireland-based, globally focused pharmaceutical sales and marketing firm Galen has acquired Swedish-headquartered POA Pharma in a multi-million pound takeover agreement.
Merck collaborates on small molecule inhibitors with Taiho and Astex
Merck has signed an exclusive worldwide research collaboration and licence agreement with two Otsuka Pharmaceutical subsidiaries, Japanese Taiho Pharmaceutical and UK-based Astex Pharmaceuticals.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.